GSK plc (GSK)
NYSE · American depositary receipt
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow GSK in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on GSK and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
GSK at a glance
Key statistics
$101.44B
Market capitalization
- Previous close
- $50.63
- Open
- $50.18
- Day range
- $49.92 – $50.43
- Volume
- 2.12M
- Average volume (30 sessions)
- 4.83M
- Shares outstanding
- 2.02B
- Beta (1 year, vs SPY)
- 0.23
Where the price sits in its year
52-week range
39% of the range
- Below the 52-week high
- -18.8%
- Above the 52-week low
- +16.9%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day average, below its 200-day
- 20-day average
- $48.15+5.2%
- 50-day average
- $49.56+2.2%
- 200-day average
- $52.35-3.3%
Between the conventional 30 and 70 bands.
+9.4%
1 week
-0.9%
1 month
-0.3%
3 months
+3.2%
Year to date
+15.3%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with GSK
GSK on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on GSK.
See the plans →
Every planScreen names like GSK
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on GSK
Put GSK on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on GSK
See whether there is an open premium alert on GSK, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
GSK headlines
- HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
GlobeNewswire Inc. · Oct 20, 2026
- Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight
GlobeNewswire Inc. · Oct 12, 2026
- GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
Benzinga · Jun 17, 2026
- Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
Investing.com · Jun 11, 2026
- GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
Benzinga · Jun 9, 2026
- GSK Targets China's Hepatitis B Market Through New Deal
Benzinga · May 11, 2026
SEC Form 4, most recent first
Insider filings
No insider transactions reported for GSK recently. ETFs and many foreign issuers do not file Form 4.
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Exchange
- NYSE
- Security
- American depositary receipt
- Employees
- 66,841
- Listed since
- Aug 18, 1976
- Website
- gsk.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.